<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Marrow transplantation is now preferred treatment, if the patient has a suitable identical twin or HLA-identical sibling donor, for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, <z:hpo ids='HP_0011009'>acute</z:hpo> myelogenous or lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> that has relapsed once, and is commonly employed for the treatment of <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> in the first remission, for <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> in the <z:hpo ids='HP_0011010'>chronic</z:hpo> phase, and for certain <z:e sem="disease" ids="C0242354" disease_type="Disease or Syndrome" abbrv="">congenital disorders</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The results of transplantation from HLA-nonidentical donors appears promising, but the follow-up is short at this time </plain></SENT>
<SENT sid="2" pm="."><plain>The low incidence of relapse or nonrelapse mortality beyond the first 3-5 years with follow-up now to almost 20 years from transplantation signifies that surviving patients are cured of their disease and are likely to have survival similar to the <z:mpath ids='MPATH_458'>normal</z:mpath> population thereafter </plain></SENT>
<SENT sid="3" pm="."><plain>They will probably lead <z:mpath ids='MPATH_458'>normal</z:mpath> productive lives in society </plain></SENT>
<SENT sid="4" pm="."><plain>These data support applying criteria for insurance candidacy of patients who have survived more than 5 years from marrow transplantation which are similar to criteria applied to other <z:mpath ids='MPATH_458'>normal</z:mpath> individuals </plain></SENT>
</text></document>